United Kingdom signs deals for 90 million COVID-19 vaccine doses

The findings related to the phase 1 human trials of the vaccine will be published in the Lancet Medical Journal

The findings related to the phase 1 human trials of the vaccine will be published in the Lancet Medical Journal

"We hope this means the immune system will remember the virus, so that our vaccine will protect people for an extended period", study lead author Andrew Pollard of the University of Oxford said.

"As well as continuing to test our vaccine in phase-three trials, we need to learn more about the virus - for example, we still do not know how strong an immune response we need to provoke to effectively protect against Sars-Cov-2 infection".

He tweeted: "We have already ordered 100 million doses of this vaccine, should it succeed".

"We're very encouraged", Hill said.

Boris Johnson, while sounding caution, said it was an "important step in the right direction".

Are NFL owners taking players’ health concerns seriously?
Watt and Russell Wilson - criticized the league Sunday for its lack of safety protocols as training camps begin to open. The NFL Players Association has to sign off on the proposal to allow more than 20 players in a building at a time.


"We are seeing good immune response in nearly everybody", said Dr. Adrian Hill, director of the Jenner Institute at Oxford University.

Earlier today, United Kingdom has signed agreements to buy 90 million doses of vaccines in development by drugmakers including Pfizer Inc., BioNTech SE and Valneva SE, joining countries around the world racing to secure supplies of protection against the pandemic.

The results will be closely scrutinized as governments around the world seek to end a pandemic that's killed more than 600,000 people and triggered economic turmoil since erupting earlier this year. The university is working together with the pharmaceutical company AstraZeneca, and others.

Scientists are now expanding the trials to include adults aged over 70, and a small number of children.

"Today's data increases our confidence that the vaccine will work and allows us to continue our plans to manufacture the vaccine at scale for broad and equitable access around the world", AstraZeneca's Mene Pangalos said.

Ronaldo scores twice as Juventus beat Lazio in Serie A
Immobile converted the penalty himself and Szczesny denied Lazio an equaliser when he palmed away a Sergej Milinkovic-Savic free kick.


Still, much remains unknown about COVID-19 vaccines in development, particularly the staying power of any immune responses and effectiveness in older adults or other specific groups, including people with chronic health problems and ethnic or racial groups more severely affected by the disease.

Vaccine: In a significant development, the Covid-19 vaccine jointly developed by British-Swedish company AstraZeneca and the University of Oxford has been found to be safe and induced an immune response in early-stage clinical trials.

The Oxford/AstraZeneca and CanSino teams released results from early trials of COVID-19 vaccines that use harmless versions of another virus, or viral vector, to deliver genetic material from the novel coronavirus into cells to generate an immune response.

The UK government has also agreed in principle for Valneva to supply 60 million doses of a vaccine it is developing, and a further 40 million if it's found to be "safe, effective and suitable".

Russian Federation denies involvement in alleged hacking of COVID-19 vaccine research
Security agencies in the US and Canada later issued their own statements backing up the findings. Ms Nandy said: "By prevaricating about issues like Salisbury, we let the Tories off the hook".


Latest News